
Fate Therapeutics has announced that it has begun enrollment for the phase 1 clinical trial of FT825/ONO-8250, a multiplexed-engineered, chimeric …

Tolremo Therapeutics has announced that it has dosed the first patient in its first-in-human clinical trial to assess the safety, …

Phase Ib clinical studies are set to begin, which will evaluate Darzalex (daratumumab) in combination with atezolizumab in a solid …
Bristol-Myers Squibb will begin early-phase trials of its immuno-oncology treatment Opdivo with other cancer treatments, to see if the combination …
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

